Autoimmune encephalitis: novel therapeutic targets at the preclinical level

References

• Dalmau J, Graus F. Antibody-mediated encephalitis. N Engl J Med. 2018;378(9):840–851.
   PubMed Web of Science ®Google Scholar
• Buckley C, Oger J, Clover L, et al. Potassium channel antibodies in two patients with reversible limbic encephalitis. Ann Neurol. 2001;50(1):73–78.
   PubMed Web of Science ®Google Scholar
• Vincent A, Buckley C, Schott JM, et al., Potassium channel antibody-associated encephalopathy: a potentially immunotherapy-responsive form of limbic encephalitis. Brain. 2004;127(Pt 3):701–712.
   PubMed Web of Science ®Google Scholar
• Lai M, Huijbers MG, Lancaster E, et al. Investigation of LGI1 as the antigen in limbic encephalitis previously attributed to potassium channels: a case series. Lancet Neurol. 2010;9(8):776–785.
   PubMed Web of Science ®Google Scholar
• Irani SR, Alexander S, Waters P, et al. Antibodies to Kv1 potassium channel-complex proteins leucine-rich, glioma inactivated 1 protein and contactin-associated protein-2 in limbic encephalitis, Morvan’s syndrome and acquired neuromyotonia. Brain. 2010;133(9):2734–2748.
   PubMed Web of Science ®Google Scholar
• Vitaliani R, Mason W, Ances B, et al. Paraneoplastic encephalitis, psychiatric symptoms, and hypoventilation in ovarian teratoma. Ann Neurol. 2005;58(4):594–604.
   PubMed Web of Science ®Google Scholar
• Dalmau J, Tuzun E, Wu HY, et al., Paraneoplastic anti-N-methyl-D-aspartate receptor encephalitis associated with ovarian teratoma. Ann Neurol. 2007;61(1):25–36.
   PubMed Web of Science ®Google Scholar
• Dalmau J, Geis C, Graus F. Autoantibodies to synaptic receptors and neuronal cell surface proteins in autoimmune diseases of the central nervous system. Physiol Rev. 2017;97(2):839–887.
   PubMed Web of Science ®Google Scholar
• Irani SR, Gelfand JM, Al-Diwani A, et al. Cell-surface central nervous system autoantibodies: clinical relevance and emerging paradigms. Ann Neurol. 2014;76(2):168–184.
   PubMed Web of Science ®Google Scholar
• Gleichman AJ, Spruce LA, Dalmau J, et al. Anti-NMDA receptor encephalitis antibody binding is dependent on amino acid identity of a small region within the GluN1 amino terminal domain. J Neurosci. 2012;32(32):11082–11094.
   PubMed Web of Science ®Google Scholar
• Ramanathan S, Al-Diwani A, Waters P, et al. The autoantibody-mediated encephalitides: from clinical observations to molecular pathogenesis. J Neurol. 2019. 10.1007/s00415-019-09590-9.
   Web of Science ®Google Scholar
• Planaguma J, Leypoldt F, Mannara F, et al. Human N-methyl D-aspartate receptor antibodies alter memory and behaviour in mice. Brain. 2015;138(Pt 1):94–109.
   PubMed Web of Science ®Google Scholar
• Geis C, Weishaupt A, Hallermann S, et al. Stiff person syndrome-associated autoantibodies to amphiphysin mediate reduced GABAergic inhibition. Brain. 2010;133(11):3166–3180.
   PubMed Web of Science ®Google Scholar
• Petit-Pedrol M, Sell J, Planaguma J, et al. LGI1 antibodies alter Kv1.1 and AMPA receptors changing synaptic excitability, plasticity and memory. Brain. 2018;141(11):3144–3159.
   PubMedGoogle Scholar
• Hughes EG, Peng X, Gleichman AJ, et al., Cellular and synaptic mechanisms of anti-NMDA receptor encephalitis. J Neurosci. 2010;30(17):5866–5875.
   PubMed Web of Science ®Google Scholar
• Haselmann H, Mannara F, Werner C, et al., Human autoantibodies against the AMPA receptor subunit GluA2 induce receptor reorganization and memory dysfunction. Neuron. 2018;100(1):91–105 e109.
   PubMed Web of Science ®Google Scholar
• Rauschenberger V, von Wardenburg N, Schaefer N, et al. Glycine receptor autoantibodies impair receptor function and induce motor dysfunction. Ann Neurol. 2020;88(3):544–561.
   PubMed Web of Science ®Google Scholar
• Ramberger M, Berretta A, Tan JMM, et al. Distinctive binding properties of human monoclonal LGI1 autoantibodies determine pathogenic mechanisms. Brain. 2020;143(6):1731–1745.
   PubMedGoogle Scholar
• Kornau HC, Kreye J, Stumpf A, et al. Human cerebrospinal fluid monoclonal LGI1 autoantibodies increase neuronal excitability. Ann Neurol. 2020;87(3):405–418.
   PubMed Web of Science ®Google Scholar
• Ohkawa T, Fukata Y, Yamasaki M, et al. Autoantibodies to epilepsy-related LGI1 in limbic encephalitis neutralize LGI1-ADAM22 interaction and reduce synaptic AMPA receptors. J Neurosci. 2013;33(46):18161–18174.
   PubMed Web of Science ®Google Scholar
• Leypoldt F, Wandinger KP, Bien CG, et al. Autoimmune Encephalitis. Eur Neurol Rev. 2013;8(1):31–37.
   PubMedGoogle Scholar
• Dubey D, Pittock SJ, Kelly CR, et al. Autoimmune encephalitis epidemiology and a comparison to infectious encephalitis. Ann Neurol. 2018;83(1):166–177.
   PubMed Web of Science ®Google Scholar
• Gable MS, Sheriff H, Dalmau J, et al. The frequency of autoimmune N-methyl-D-aspartate receptor encephalitis surpasses that of individual viral etiologies in young individuals enrolled in the California Encephalitis Project. Clin Infect Dis. 2012;54(7):899–904.
   PubMed Web of Science ®Google Scholar
• Graus F, Titulaer MJ, Balu R, et al. A clinical approach to diagnosis of autoimmune encephalitis. Lancet Neurol. 2016;15(4):391–404.
   PubMed Web of Science ®Google Scholar
• Lai M, Hughes EG, Peng X, et al. AMPA receptor antibodies in limbic encephalitis alter synaptic receptor location. Ann Neurol. 2009;65(4):424–434.
   PubMed Web of Science ®Google Scholar
• Hoftberger R, Titulaer MJ, Sabater L, et al. Encephalitis and GABAB receptor antibodies: novel findings in a new case series of 20 patients. Neurology. 2013;81(17):1500–1506.
   PubMed Web of Science ®Google Scholar
• Titulaer MJ, McCracken L, Gabilondo I, et al. Treatment and prognostic factors for long-term outcome in patients with anti-NMDA receptor encephalitis: an observational cohort study. Lancet Neurol. 2013;12(2):157–165.
   PubMed Web of Science ®Google Scholar
• Chefdeville A, Treilleux I, Mayeur ME, et al. Immunopathological characterization of ovarian teratomas associated with anti-N-methyl-D-aspartate receptor encephalitis. Acta Neuropathol Commun. 2019;7(1):38.
   PubMedGoogle Scholar
• Makuch M, Wilson R, Al-Diwani A, et al. N-methyl-D-aspartate receptor antibody production from germinal center reactions: therapeutic implications. Ann Neurol. 2018;83(3):553–561.
   PubMed Web of Science ®Google Scholar
• Tuzun E, Zhou L, Baehring JM, et al. Evidence for antibody-mediated pathogenesis in anti-NMDAR encephalitis associated with ovarian teratoma. Acta Neuropathol. 2009;118(6):737–743.
   PubMed Web of Science ®Google Scholar
• Dai Y, Zhang J, Ren H, et al. Surgical outcomes in patients with anti-N-methyl D-aspartate receptor encephalitis with ovarian teratoma. Am J Obstet Gynecol. 2019;221(5):485 e481–485 e410.
   Web of Science ®Google Scholar
• Pruss H, Finke C, Holtje M, et al. N-methyl-D-aspartate receptor antibodies in herpes simplex encephalitis. Ann Neurol. 2012;72(6):902–911.
   PubMed Web of Science ®Google Scholar
• Armangue T, Spatola M, Vlagea A, et al. Frequency, symptoms, risk factors, and outcomes of autoimmune encephalitis after herpes simplex encephalitis: a prospective observational study and retrospective analysis. Lancet Neurol. 2018;17(9):760–772.
   PubMed Web of Science ®Google Scholar
• Sun B, Ramberger M, O’Connor KC, et al. The B cell immunobiology that underlies CNS autoantibody-mediated diseases. Nat Rev Neurol. 2020;16(9):481–492.
   PubMed Web of Science ®Google Scholar
• Binks S, Varley J, Lee W, et al. Distinct HLA associations of LGI1 and CASPR2-antibody diseases. Brain. 2018;141(8):2263–2271.
   PubMedGoogle Scholar
• Kim TJ, Lee ST, Moon J, et al. Anti-LGI1 encephalitis is associated with unique HLA subtypes. Ann Neurol. 2017;81(2):183–192.
   PubMed Web of Science ®Google Scholar
• Bien CG, Vincent A, Barnett MH, et al. Immunopathology of autoantibody-associated encephalitides: clues for pathogenesis. Brain. 2012;135(Pt 5):1622–1638.
   PubMed Web of Science ®Google Scholar
• Thompson J, Bi M, Murchison AG, et al., The importance of early immunotherapy in patients with faciobrachial dystonic seizures. Brain. 2018;141(2):348–356.
   PubMed Web of Science ®Google Scholar
• Dalmau J, Gleichman AJ, Hughes EG, et al. Anti-NMDA-receptor encephalitis: case series and analysis of the effects of antibodies. Lancet Neurol. 2008;7(12):1091–1098.
   PubMed Web of Science ®Google Scholar
• Mikasova L, De Rossi P, Bouchet D, et al. Disrupted surface cross-talk between NMDA and Ephrin-B2 receptors in anti-NMDA encephalitis. Brain. 2012;135(Pt 5):1606–1621.
   PubMed Web of Science ®Google Scholar
• Planaguma J, Haselmann H, Mannara F, et al. Ephrin-B2 prevents N-methyl-D-aspartate receptor antibody effects on memory and neuroplasticity. Ann Neurol. 2016;80(3):388–400.
   PubMed Web of Science ®Google Scholar
• Geis C, Grunewald B, Weishaupt A, et al. Human IgG directed against amphiphysin induces anxiety behavior in a rat model after intrathecal passive transfer. J Neural Transm (Vienna). 2012;119(8):981–985.
   PubMed Web of Science ®Google Scholar
• Werner C, Pauli M, Doose S, et al. Human autoantibodies to amphiphysin induce defective presynaptic vesicle dynamics and composition. Brain. 2016;139(Pt 2):365–379.
   PubMedGoogle Scholar
• Dubey D, Britton J, McKeon A, et al. Randomized placebo-controlled trial of intravenous immunoglobulin in autoimmune LGI1/CASPR2 epilepsy. Ann Neurol. 2020;87(2):313–323.
   PubMed Web of Science ®Google Scholar
• Dalmau J, Armangue T, Planaguma J, et al. An update on anti-NMDA receptor encephalitis for neurologists and psychiatrists: mechanisms and models. Lancet Neurol. 2019;18(11):1045–1057.
   PubMed Web of Science ®Google Scholar
• Schubert J, Bramer D, Huttner HB, et al. Management and prognostic markers in patients with autoimmune encephalitis requiring ICU treatment. Neurol Neuroimmunol Neuroinflamm. 2019;6(1):e514.
   PubMed Web of Science ®Google Scholar
• Ariño H, Armangué T, Petit-Pedrol M, et al. Anti-LGI1-associated cognitive impairment: presentation and long-term outcome. Neurology. 2016;87(8):759–765.
   PubMed Web of Science ®Google Scholar
• van Sonderen A, Thijs RD, Coenders EC, et al. Anti-LGI1 encephalitis: clinical syndrome and long-term follow-up. Neurology. 2016;87(14):1449–1456.
   PubMed Web of Science ®Google Scholar
• van Sonderen A, Ariño H, Petit-Pedrol M, et al. The clinical spectrum of Caspr2 antibody-associated disease. Neurology. 2016;87(5):521–528.
   PubMed Web of Science ®Google Scholar
• Keddie S, Crisp SJ, Blackaby J. et al. Plasma cell depletion with bortezomib in the treatment of refractory N-methyl-d-aspartate (NMDA) receptor antibody encephalitis. Rational developments in neuroimmunological treatment. Eur J Neurol. 2018;25(11):1384–1388.
   PubMed Web of Science ®Google Scholar
• Scheibe F, Pruss H, Mengel AM, et al. Bortezomib for treatment of therapy-refractory anti-NMDA receptor encephalitis. Neurology. 2017;88(4):366–370.
   PubMed Web of Science ®Google Scholar
• Shin YW, Lee ST, Kim TJ, et al. Bortezomib treatment for severe refractory anti-NMDA receptor encephalitis. Ann Clin Transl Neurol. 2018;5(5):598–605.
   PubMed Web of Science ®Google Scholar
• Sveinsson O, Granqvist M, Forslin Y, et al. Successful combined targeting of B- and plasma cells in treatment refractory anti-NMDAR encephalitis. J Neuroimmunol. 2017;312:15–18.
   PubMed Web of Science ®Google Scholar
• Drachman DB. Myasthenia gravis. N Engl J Med. 1994;330(25):1797–1810.
   PubMed Web of Science ®Google Scholar
• Ladepeche L, Planaguma J, Thakur S, et al. NMDA receptor autoantibodies in autoimmune encephalitis cause a subunit-specific nanoscale redistribution of NMDA receptors. Cell Rep. 2018;23(13):3759–3768.
   PubMed Web of Science ®Google Scholar
• Takasu MA, Dalva MB, Zigmond RE, et al. Modulation of NMDA receptor-dependent calcium influx and gene expression through EphB receptors. Science. 2002;295(5554):491–495.
   PubMed Web of Science ®Google Scholar
• Nolt MJ, Lin Y, Hruska M, et al. EphB controls NMDA receptor function and synaptic targeting in a subunit-specific manner. J Neurosci. 2011;31(14):5353–5364.
   PubMed Web of Science ®Google Scholar
• Paul SM, Doherty JJ, Robichaud AJ, et al. The major brain cholesterol metabolite 24(S)-hydroxycholesterol is a potent allosteric modulator of N-methyl-D-aspartate receptors. J Neurosci. 2013;33(44):17290–17300.
   PubMed Web of Science ®Google Scholar
• Linsenbardt AJ, Taylor A, Emnett CM, et al. Different oxysterols have opposing actions at N-methyl-D-aspartate receptors. Neuropharmacology. 2014;85:232–242.
   PubMed Web of Science ®Google Scholar
• Sun MY, Linsenbardt AJ, Emnett CM, et al. 24(S)-hydroxycholesterol as a modulator of neuronal signaling and survival. Neuroscientist. 2016;22(2):132–144.
   PubMed Web of Science ®Google Scholar
• Hackos DH, Hanson JE. Diverse modes of NMDA receptor positive allosteric modulation: mechanisms and consequences. Neuropharmacology. 2017;112(Pt A):34–45.
   PubMed Web of Science ®Google Scholar
• Warikoo N, Brunwasser SJ, Benz A, et al., Positive allosteric modulation as a potential therapeutic strategy in anti-NMDA receptor encephalitis. J Neurosci. 2018;38(13):3218–3229.
   PubMed Web of Science ®Google Scholar
• Mannara F, Radosevic M, Planaguma J, et al. Allosteric modulation of NMDA receptors prevents the antibody effects of patients with anti-NMDAR encephalitis. Brain. 2020;143(9):2709–2720.
   PubMedGoogle Scholar
• Pruss H, Kirmse K. Pathogenic role of autoantibodies against inhibitory synapses. Brain Res. 2018;1701:146–152.
   PubMed Web of Science ®Google Scholar
• Holmoy T, Geis C. The immunological basis for treatment of stiff person syndrome. J Neuroimmunol. 2011;231(1–2):55–60.
   PubMed Web of Science ®Google Scholar
• Voglmaier SM, Kam K, Yang H, et al. Distinct endocytic pathways control the rate and extent of synaptic vesicle protein recycling. Neuron. 2006;51(1):71–84.
   PubMed Web of Science ®Google Scholar
• Crisp SJ, Dixon CL, Jacobson L, et al. Glycine receptor autoantibodies disrupt inhibitory neurotransmission. Brain. 2019;142(11):3398–3410.
   PubMedGoogle Scholar
• Papanastasiou D, Poulas K, Kokla A, et al. Prevention of passively transferred experimental autoimmune myasthenia gravis by Fab fragments of monoclonal antibodies directed against the main immunogenic region of the acetylcholine receptor. J Neuroimmunol. 2000;104(2):124–132.
   PubMed Web of Science ®Google Scholar
• Papanastasiou D, Mamalaki A, Eliopoulos E, et al. Construction and characterization of a humanized single chain Fv antibody fragment against the main immunogenic region of the acetylcholine receptor. J Neuroimmunol. 1999;94(1–2):182–195.
   PubMed Web of Science ®Google Scholar
• Buchegger F, Haskell CM, Schreyer M, et al. Radiolabeled fragments of monoclonal antibodies against carcinoembryonic antigen for localization of human colon carcinoma grafted into nude mice. J Exp Med. 1983;158(2):413–427.
   PubMed Web of Science ®Google Scholar
• Gil D, Schrum AG. Strategies to stabilize compact folding and minimize aggregation of antibody-based fragments. Adv Biosci Biotechnol. 2013;4(4a):73–84.
   PubMedGoogle Scholar
• Holliger P, Hudson PJ. Engineered antibody fragments and the rise of single domains. Nat Biotechnol. 2005;23(9):1126–1136.
   PubMed Web of Science ®Google Scholar
• Veronese FM, Mero A. The impact of PEGylation on biological therapies. BioDrugs. 2008;22(5):315–329.
   PubMed Web of Science ®Google Scholar
• Adams R, Griffin L, Compson JE, et al. Extending the half-life of a fab fragment through generation of a humanized anti-human serum albumin Fv domain: an investigation into the correlation between affinity and serum half-life. MAbs. 2016;8(7):1336–1346.
   PubMed Web of Science ®Google Scholar
• Kreye J, Wenke NK, Chayka M, et al. Human cerebrospinal fluid monoclonal N-methyl-D-aspartate receptor autoantibodies are sufficient for encephalitis pathogenesis. Brain. 2016;139(Pt 10):2641–2652.
   PubMed Web of Science ®Google Scholar
• Malviya M, Barman S, Golombeck KS, et al. NMDAR encephalitis: passive transfer from man to mouse by a recombinant antibody. Ann Clin Transl Neurol. 2017;4(11):768–783.
   PubMed Web of Science ®Google Scholar
• Wenke NK, Kreye J, Andrzejak E, et al. N-methyl-D-aspartate receptor dysfunction by unmutated human antibodies against the NR1 subunit. Ann Neurol. 2019;85(5):771–776.
   PubMed Web of Science ®Google Scholar
• Lennon VA, Kryzer TJ, Pittock SJ, et al. IgG marker of optic-spinal multiple sclerosis binds to the aquaporin-4 water channel. J Exp Med. 2005;202(4):473–477.
   PubMed Web of Science ®Google Scholar
• Papadopoulos MC, Verkman AS. Aquaporin 4 and neuromyelitis optica. Lancet Neurol. 2012;11(6):535–544.
   PubMed Web of Science ®Google Scholar
• Tradtrantip L, Zhang H, Saadoun S, et al. Anti-aquaporin-4 monoclonal antibody blocker therapy for neuromyelitis optica. Ann Neurol. 2012;71(3):314–322.
   PubMed Web of Science ®Google Scholar
• Tradtrantip L, Asavapanumas N, Verkman AS. Emerging therapeutic targets for neuromyelitis optica spectrum disorder. Expert Opin Ther Targets. 2020;24(3):219–229.
   PubMed Web of Science ®Google Scholar
• Duan T, Tradtrantip L, Phuan PW, et al. Affinity-matured ‘aquaporumab’ anti-aquaporin-4 antibody for therapy of seropositive neuromyelitis optica spectrum disorders. Neuropharmacology. 2020;162:107827.
   PubMed Web of Science ®Google Scholar
• Krumbholz M, Meinl E. B cells in MS and NMO: pathogenesis and therapy. Semin Immunopathol. 2014;36(3):339–350.
   PubMed Web of Science ®Google Scholar
• Jefferis R, Lund J, Pound JD. IgG-Fc-mediated effector functions: molecular definition of interaction sites for effector ligands and the role of glycosylation. Immunol Rev. 1998;163:59–76.
   PubMed Web of Science ®Google Scholar
• Albert H, Collin M, Dudziak D, et al. In vivo enzymatic modulation of IgG glycosylation inhibits autoimmune disease in an IgG subclass-dependent manner. Proc Natl Acad Sci U S A. 2008;105(39):15005–15009.
   PubMed Web of Science ®Google Scholar
• van Timmeren MM, van der Veen BS, Stegeman CA, et al. IgG glycan hydrolysis attenuates ANCA-mediated glomerulonephritis. J Am Soc Nephrol. 2010;21(7):1103–1114.
   PubMed Web of Science ®Google Scholar
• Tradtrantip L, Ratelade J, Zhang H, et al. Enzymatic deglycosylation converts pathogenic neuromyelitis optica anti-aquaporin-4 immunoglobulin G into therapeutic antibody. Ann Neurol. 2013;73(1):77–85.
   PubMed Web of Science ®Google Scholar
• von Pawel-rammingen U, Johansson BP, Björck L. IdeS, a novel streptococcal cysteine proteinase with unique specificity for immunoglobulin G. Embo J. 2002;21(7):1607–1615.
   PubMed Web of Science ®Google Scholar
• Johansson BP, Shannon O, Björck L. IdeS: a bacterial proteolytic enzyme with therapeutic potential. PLoS One. 2008;3(2):e1692.
   PubMed Web of Science ®Google Scholar
• Winstedt L, Järnum S, Nordahl EA, et al. Complete removal of extracellular IgG antibodies in a randomized dose-escalation phase I study with the bacterial enzyme IdeS–a novel therapeutic opportunity. PLoS One. 2015;10(7):e0132011.
   PubMed Web of Science ®Google Scholar
• Alexander T, Sarfert R, Klotsche J, et al. The proteasome inhibitior bortezomib depletes plasma cells and ameliorates clinical manifestations of refractory systemic lupus erythematosus. Ann Rheum Dis. 2015;74(7):1474–1478.
   PubMed Web of Science ®Google Scholar
• Zhang C, Tian DC, Yang CS, et al. Safety and efficacy of bortezomib in patients with highly relapsing neuromyelitis optica spectrum disorder. JAMA Neurol. 2017;74(8):1010–1012.
   PubMed Web of Science ®Google Scholar
• Wickel J, Chung HY, Platzer S, et al. Generate-Boost: study protocol for a prospective, multicenter, randomized controlled, double-blinded phase II trial to evaluate efficacy and safety of bortezomib in patients with severe autoimmune encephalitis. Trials. 2020;21(1):625.
   PubMedGoogle Scholar
• Palumbo A, Chanan-Khan A, Weisel K, et al. Daratumumab, bortezomib, and dexamethasone for multiple myeloma. N Engl J Med. 2016;375(8):754–766.
   PubMed Web of Science ®Google Scholar
• Scheibe F, Ostendorf L, Reincke SM, et al. Daratumumab treatment for therapy-refractory anti-CASPR2 encephalitis. J Neurol. 2020;267(2):317–323.
   PubMed Web of Science ®Google Scholar
• Geis C, Planaguma J, Carreno M, et al. Autoimmune seizures and epilepsy. J Clin Invest. 2019;129(3):926–940.
   PubMed Web of Science ®Google Scholar
• Barnett C, Tabasinejad R, Bril V. Current pharmacotherapeutic options for myasthenia gravis. Expert Opin Pharmacother. 2019;20(18):2295–2303.
   PubMed Web of Science ®Google Scholar
• Halliley JL, Tipton CM, Liesveld J, et al. Long-lived plasma cells are contained within the CD19(-)CD38(hi)CD138(+) subset in human bone marrow. Immunity. 2015;43(1):132–145. .
   PubMed Web of Science ®Google Scholar
• Chen D, Gallagher S, Monson NL, et al. Inebilizumab, a B cell-depleting anti-CD19 antibody for the treatment of autoimmune neurological diseases: insights from preclinical studies. J Clin Med. 2016;5:12.
   Web of Science ®Google Scholar
• Cree BAC, Bennett JL, Kim HJ, et al. Inebilizumab for the treatment of neuromyelitis optica spectrum disorder (N-MOmentum): a double-blind, randomised placebo-controlled phase 2/3 trial. Lancet. 2019;394(10206):1352–1363.
   PubMed Web of Science ®Google Scholar